FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321877988> ?p ?o ?g. }

• W2321877988 endingPage "506" @default.
• W2321877988 startingPage "505" @default.
• W2321877988 abstract "<h3>Background</h3> The data on how to optimally retreat patients with RA with rituximab (RTX) have been limited so far. <h3>Objectives</h3> The aim of this analysis was to compare two common retreatment strategies: A fixed retreatment approach and retreatment when a flare occurs. <h3>Methods</h3> Pooled data from the Collaborating European Registries for Rituximab in RA (CERERRA) project were used. We identified RA patients who had received at least 2 retreatments (3 courses) with RTX and who had available information about the strategy for retreatment (according to the physician9s opinion). The two retreatment strategies were compared by applying an adjusted mixed model analysis with DAS28 improvement as the dependent variable. <h3>Results</h3> A total of 800 patients were retreated at least twice: 616 patients retreated because of a flare (442 at 1st and 174 at 2nd retreatment) and 184 receiving fixed retreatment (128 at 1st and 56 at 2nd retreatment). Baseline characteristics (incl. age, sex, seropositivity, disease duration, number of prior DMARDs and biologics) at first course of RTX did not differ significantly between the two groups. However, patients retreated on flare had, as expected, a significantly higher DAS28-ESR at the time of 1st retreatment (5.1±1.3 vs. 4.1±1.4, p<0.0001), and a higher HAQ (1.5±0.7 vs. 1.3±0.8, p=0.001). They had also a slightly higher baseline (at the time of RTX start) DAS28 (6.3±1.0 vs. 6.1±1.2, p=0.03). Those retreated on flare were more likely to be treated with corticosteroids (58% vs. 46%, p=0.01) but less likely to receive concomitant DMARDs (82% vs. 92%, p=0.005). The baseline (=start of each cycle) deltaDAS28 (compared to the DAS28 at the time of RTX start) for the two groups is shown in figure 1. Patients receiving fixed retreatment had a significantly higher (in absolute number) deltaDAS28 (p<0.0001) at the start of each cycle, compared to those retreated on-flare. In the adjusted mixed model analysis, we compared the two retreatment groups for the 1st and the 2nd retreatment separately using estimated marginal means. For the 1st retreatment a fixed retreatment yielded significantly better results than the “on-flare”: mean deltaDAS28=-2.4 (95% CI: -3.0; -1.7) vs. -1.8 (95% CI: -3.6; -0.03), p<0.0001. Similar results were found for the 2nd retreatment: mean deltaDAS28=-2.6 (95% CI: -3.1; -2.2) vs. -1.6 (95% CI: -1.8; -1.4), p<0.0001. <h3>Conclusions</h3> A fixed RTX retreatment strategy in RA seems to be more effective than the retreatment “on-flare” strategy. <h3>Disclosure of Interest</h3> K. Chatzidionysiou: None declared, E. Lie: None declared, E. Nasonov: None declared, G. Lukina: None declared, M. Hetland: None declared, U. Tarp: None declared, K. Pavelka: None declared, C. Gabay: None declared, D. Nordström: None declared, H. Canhão: None declared, M. Tomsic: None declared, P. van Riel: None declared, J. Gomez-Reino: None declared, I. Ancuta: None declared, T. Kvien Grant/research support: research funding to the Diakonhjemmet Hospital from AbbVie, BMS, MSD/Schering-Plough, Pfizer/Wyeth, Roche and UCB, Consultant for: AbbVie, BMS, Celltrion, Eli Lilly, Hospira, MSD/Schering-Plough, Orion Pharma, Pfizer/Wyeth, Roche, UCB, R. van Vollenhoven: None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2571" @default.
• W2321877988 created "2016-06-24" @default.
• W2321877988 creator A5000798254 @default.
• W2321877988 creator A5002976325 @default.
• W2321877988 creator A5012009272 @default.
• W2321877988 creator A5021089252 @default.
• W2321877988 creator A5035671675 @default.
• W2321877988 creator A5039628338 @default.
• W2321877988 creator A5041130669 @default.
• W2321877988 creator A5043580027 @default.
• W2321877988 creator A5048248640 @default.
• W2321877988 creator A5048402348 @default.
• W2321877988 creator A5049547284 @default.
• W2321877988 creator A5057994974 @default.
• W2321877988 creator A5063586848 @default.
• W2321877988 creator A5071926023 @default.
• W2321877988 creator A5072757969 @default.
• W2321877988 creator A5089477356 @default.
• W2321877988 date "2014-06-01" @default.
• W2321877988 modified "2023-10-16" @default.
• W2321877988 title "FRI0328 Fixed versus On-Flare Retreatment with Rituximab in RA – Results from the Cererra Collaboration" @default.
• W2321877988 doi "https://doi.org/10.1136/annrheumdis-2014-eular.2571" @default.
• W2321877988 hasPublicationYear "2014" @default.
• W2321877988 type Work @default.
• W2321877988 sameAs 2321877988 @default.
• W2321877988 citedByCount "0" @default.
• W2321877988 crossrefType "journal-article" @default.
• W2321877988 hasAuthorship W2321877988A5000798254 @default.
• W2321877988 hasAuthorship W2321877988A5002976325 @default.
• W2321877988 hasAuthorship W2321877988A5012009272 @default.
• W2321877988 hasAuthorship W2321877988A5021089252 @default.
• W2321877988 hasAuthorship W2321877988A5035671675 @default.
• W2321877988 hasAuthorship W2321877988A5039628338 @default.
• W2321877988 hasAuthorship W2321877988A5041130669 @default.
• W2321877988 hasAuthorship W2321877988A5043580027 @default.
• W2321877988 hasAuthorship W2321877988A5048248640 @default.
• W2321877988 hasAuthorship W2321877988A5048402348 @default.
• W2321877988 hasAuthorship W2321877988A5049547284 @default.
• W2321877988 hasAuthorship W2321877988A5057994974 @default.
• W2321877988 hasAuthorship W2321877988A5063586848 @default.
• W2321877988 hasAuthorship W2321877988A5071926023 @default.
• W2321877988 hasAuthorship W2321877988A5072757969 @default.
• W2321877988 hasAuthorship W2321877988A5089477356 @default.
• W2321877988 hasConcept C121332964 @default.
• W2321877988 hasConcept C126322002 @default.
• W2321877988 hasConcept C141071460 @default.
• W2321877988 hasConcept C2779338263 @default.
• W2321877988 hasConcept C2779588948 @default.
• W2321877988 hasConcept C2780653079 @default.
• W2321877988 hasConcept C44870925 @default.
• W2321877988 hasConcept C71924100 @default.
• W2321877988 hasConceptScore W2321877988C121332964 @default.
• W2321877988 hasConceptScore W2321877988C126322002 @default.
• W2321877988 hasConceptScore W2321877988C141071460 @default.
• W2321877988 hasConceptScore W2321877988C2779338263 @default.
• W2321877988 hasConceptScore W2321877988C2779588948 @default.
• W2321877988 hasConceptScore W2321877988C2780653079 @default.
• W2321877988 hasConceptScore W2321877988C44870925 @default.
• W2321877988 hasConceptScore W2321877988C71924100 @default.
• W2321877988 hasIssue "Suppl 2" @default.
• W2321877988 hasLocation W23218779881 @default.
• W2321877988 hasOpenAccess W2321877988 @default.
• W2321877988 hasPrimaryLocation W23218779881 @default.
• W2321877988 hasRelatedWork W2002120878 @default.
• W2321877988 hasRelatedWork W2003938723 @default.
• W2321877988 hasRelatedWork W2047967234 @default.
• W2321877988 hasRelatedWork W2118496982 @default.
• W2321877988 hasRelatedWork W2143803333 @default.
• W2321877988 hasRelatedWork W2364998975 @default.
• W2321877988 hasRelatedWork W2439875401 @default.
• W2321877988 hasRelatedWork W4238867864 @default.
• W2321877988 hasRelatedWork W2519357708 @default.
• W2321877988 hasRelatedWork W2525756941 @default.
• W2321877988 hasVolume "73" @default.
• W2321877988 isParatext "false" @default.
• W2321877988 isRetracted "false" @default.
• W2321877988 magId "2321877988" @default.
• W2321877988 workType "article" @default.